What is the projected market size for weight-loss drugs?

Analysts estimate the weight-loss drug market could exceed $150 billion annually by the end of the decade.

Which pharmaceutical companies are active in the weight-loss drug space?

Companies like Pfizer and Novo Nordisk are actively involved, with Pfizer acquiring Metsera for $10 billion.

What strategies are companies considering for obesity treatments?

Companies are deciding between developing new, early-stage drug compounds or acquiring proven, potentially more expensive, treatments.

Home / Business and Economy / Viking CEO: Weight-Loss Deals More Intense Than Seen

Viking CEO: Weight-Loss Deals More Intense Than Seen

13 Jan

•

Summary

Weight-loss drug market projected to exceed $150 billion annually.
Pharma companies are exploring various strategies for obesity treatments.
Strategic interest in weight-loss drug deals is broader than visible.

Viking CEO: Weight-Loss Deals More Intense Than Seen

The pharmaceutical industry is intensely focused on the burgeoning weight-loss drug market, a sector projected by analysts to surpass $150 billion in annual value by 2030. This significant market growth is fueled by expanding clinical applications, increased patient adoption, enhanced manufacturing capabilities, and the development of next-generation therapies.

Viking Therapeutics CEO Brian Lian recently commented that the level of strategic interest in weight-loss drug deals is likely broader than publicly perceived, with numerous companies closely monitoring the landscape. This heightened interest follows major acquisitions, such as Pfizer's $10 billion purchase of Metsera in November 2025, which involved a competitive bidding process.